Background-Scatter factor/hepatocyte growth factor (SF/HGF) is a pleiotropic growth factor that stimulates proliferation and migration of endothelial cells (ECs) via the c-Met receptor, present on ECs as well as other cell types, including smooth muscle cells (SMCs). We studied the effects of recombinant human (rh) SF/HGF in vitro and in vivo in a rabbit model of hindlimb ischemia. We further compared these effects with those of recombinant human vascular endothelial growth factor (rhVEGF 165 ), an EC-specific mitogen. Methods and Results-In vitro, rhSF/HGF and rhVEGF 165 exhibited similar effects on proliferation and migration of ECs.
A ngiogenesis involves activation, migration, and proliferation of ECs 1 and is regulated by certain growth factors. 2 Exogenous administration of growth-regulating molecules that stimulate angiogenesis has potential utility for the treatment of tissue ischemia not amenable to conventional revascularization techniques. This strategy, referred to as "therapeutic angiogenesis," has been validated in various animal models of limb or myocardial ischemia [3] [4] [5] [6] [7] [8] and more recently in patients treated with plasmid DNA encoding for VEGF. 9, 10 SF/HGF is a recently characterized growth factor 11, 12 that has a disulfide-linked heterodimer structure and an apparent molecular weight of 80 kD. 11 Its receptor has been identified as the c-Met proto-oncogene product, a transmembrane tyrosine kinase. 12 Synthesis of SF/HGF by mesenchymal cells (eg, fibroblasts and SMCs), coupled with demonstrated effects on epithelial cells and ECs, suggests a paracrine mode of action. 13 SF/HGF is considered to be a principal mediator of mesenchymal-epithelial/endothelial interactions that contribute to embryogenesis, organ regeneration, wound healing, and angiogenesis. [13] [14] [15] [16] Indeed, previous investigations have established that SF/ HGF directly stimulates proliferation and migration of cultured ECs, 17, 18 promotes development of capillary-like structures in vitro, 18, 19 and stimulates blood vessel formation in Matrigel plugs and normal cornea. 16, 18 Furthermore, SF/HGF has been shown to be induced in skeletal muscle after ischemic injury. 14 More recently, SF/HGF has been implicated in capillary EC regeneration in the ischemically injured myocardium. 20 Previous studies from our laboratory and others have established that certain cytokines, such as platelet-derived growth factor-BB and transforming growth factor-␤ 1 , can upregulate VEGF expression in vascular SMCs and thereby exert indirect angiogenic effects, 21 even though they are nonmitogenic or even inhibitory for EC proliferation in vitro. 22, 23 Because the c-Met receptor for SF/HGF is expressed on both ECs and vascular SMCs, 24 we considered the possibility that SF/HGF could also upregulate VEGF expression in SMCs. Thus, the angiogenic potency of SF/HGF in vivo might be enhanced through coordinately regulated direct and indirect effects.
The present series of experiments demonstrates that the direct effect of SF/HGF on EC proliferation and migration is similar to that of VEGF; the combination of SF/HGF and VEGF, however, is shown to produce an additive effect on EC proliferation and a synergistic effect on EC migration. Moreover, in vitro administration of SF/HGF to HVSMCs induces upregulated expression of both VEGF mRNA and protein. In vivo, angiographic, physiological, and histological findings indicate that SF/HGF-induced angiogenesis is superior to that achieved with VEGF. SF/HGF is thus a potent agent for strategies designed to promote therapeutic angiogenesis, possibly as a result of the combination of direct effects of SF/HGF on ECs and the indirect effects, including paracrine upregulation of VEGF on SMCs, as demonstrated in vitro. 165 rhSF/HGF was produced in Chinese hamster ovary cells transfected with a plasmid encoding the full-length, natural human SF/HGF sequence. The rhSF/HGF was then converted into the bioactive, heterodimer form by a modification of the method described by Naka et al 25 and purified by conventional chromatography, as previously described. 26 The 165-amino-acid homodimeric species of rhVEGF 165 was purified from transfected Chinese hamster ovary cells as previously described. 27 The purity of the material was assessed by a silver-stained SDS-PAGE gel and the presence of a single NH 2 -terminal amino acid sequence.
Methods rhSF/HGF and rhVEGF

Cell Culture
HUVECs were prepared from umbilical cord vein as previously described 28 and grown in medium 199 (M199) (GIBCO BRL) supplemented with 20% FBS, EC growth supplement (100 g/mL), and heparin (50 U/mL). HVSMCs were cultured by explant outgrowth from unused portions of internal mammary arteries obtained at coronary artery bypass graft surgery as previously described. 29 Cells were cultured in DMEM supplemented with 10% FBS.
Northern Blot Analysis in Cultured HVSMCs
Confluent HVSMCs (passages 3 to 5) were growth-arrested in filtered DMEM containing 0.5% FBS for 48 hours before each experiment. The cells were then treated with rhSF/HGF for various time intervals and different concentrations as indicated. Stimulation of HVSMCs with PMA (Sigma Chemical Co) was used as a positive control for VEGF gene expression. 30 Total RNA from HVSMCs was isolated by phenol/chloroform extraction, 31 and Northern blot analysis was performed as previously described. 21 The DNA probe for human VEGF was a 675-bp EcoRI/Bgl II fragment (gift of N. Ferrara, Genentech Inc).
RT-PCR Analysis in Cultured HVSMCs
First-strand cDNA synthesis and PCR analysis were performed according to standard procedures. 32, 33 The primer chosen for human VEGF (Genbank accession number M32977) was, for sense, (5Ј-3Ј) GAACTTTCTGCTGTCTTGGG and, for antisense, (5Ј-3Ј) TCACCGCCTCGGCTTGTCAC. PCR resulted in three bands (438, 570, and 642 bp) corresponding to the three principal VEGF isoforms, 121, 165, and 189, respectively, expressed in HVSMCs. 30 For human GAPDH (X01677), the following primers were used: sense, (5Ј-3Ј) TGAAGGTCGGAGTCAACGGATTTG and antisense, (5Ј-3Ј) CATGTGGGCCATGAGGTCCACCAC. PCR resulted in a 983-bp band. The linear phase of the exponential range amplification was determined for each primer set to allow semiquantitative PCR analysis. 34 The number of cycles was then chosen in the linear phase of amplification: 29 cycles for VEGF and 20 cycles for GAPDH. Ten microliters of each PCR reaction mixture was electrophoresed in a 1.5% agarose gel, and bands were visualized by ethidium bromide staining. Bands were quantified densitometrically by scanning and analyzing with Eagle's Eye II software. To normalize signals for VEGF 165 , the value was divided by the signal for GAPDH, a widely invariant and highly expressed gene. The data presented as relative values (VEGF 165 /GAPDH) were plotted against time. The results represent three independent amplifications from two separate studies.
Analysis of VEGF Protein Expression in Cultured HVSMCs
For analysis of VEGF protein expression in SMCs by Western blotting, cells were lysed by addition of 1 mL RIPA buffer (1% NP-40, 0.5% sodium deoxycholic acid, 0.1% SDS in PBS, pH 7.4; 1 mol/L leupeptin; 5 mol/L aprotinin; 1 mmol/L PMSF; and 1 mol/L pepstatin, all Sigma Chemical Co) per 100-mm plate. Protein extracts (100 g) were separated on a 10% SDS-PAGE and transferred to a 0.2-m PVDF membrane (Bio Rad). The membranes were blocked in 10% nonfat dry milk/0.2% Tween-20 in PBS, pH 7.4, then immunoblotted with a rabbit polyclonal anti-human VEGF antibody (1:200; Santa Cruz) overnight at 4°C. Blots were washed with 0.2% Tween-20 in PBS and incubated with horseradish peroxidase-linked goat anti-rabbit antibody (1:7500; Santa Cruz) for 45 minutes. Immunoreactive bands were visualized with ECL reagent (Amersham).
EC Proliferation Assay
For evaluation of proliferation, the colorimetric MTT assay was performed as previously described. 35 Briefly, HUVECs were seeded in a 96-well plate (5000 cells/well) in 0.2 mL M199 (GIBCO BRL) containing 5% FBS. MTT was dissolved in PBS at 5 mg/mL to constitute a stock solution. After the incubation of HUVECs with rhSF/HGF, rhVEGF 165 , or a combination of the two for 48 hours, the MTT solution was added to each well (10 L/100 L medium), and plates were incubated at 37°C for 4 hours. The medium was decanted, and DMSO was added to all wells to dissolve the dark blue crystals. Plates were read on an SLT EAR 400 AT automatic plate reader (SLT Labinstruments) with a test wavelength of 560 nm and a reference wavelength of 650 nm. All experiments were performed in quadruplicate.
EC Migration Assay
EC migration assays were performed in a 48-well microchemotaxis chamber (Neuroprobe Inc). 36 PVP-free polycarbonate filters with a pore size of 8 m (Nuclepore Corp) were coated with 0.1% gelatin for at least 6 hours at room temperature and dried under sterile air. Test substances were diluted to appropriate concentrations in M199 supplemented with 1% FBS, and 25 L of the final dilution was placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early-passage 2-6 HUVEC cultures were washed and trypsinized for the
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EC ϭ endothelial cell HUVEC ϭ human endothelial cell HVSMC ϭ human vascular smooth muscle cell PMA ϭ phorbol-12-myristate 13-acetate rh ϭ recombinant human RT-PCR ϭ reverse transcription-polymerase chain reaction SF/HGF ϭ scatter factor/hepatocyte growth factor SMC ϭ smooth muscle cell VEGF ϭ vascular endothelial growth factor minimum time required to achieve cell detachment. After the filter was placed between the lower and upper chambers, 2.5ϫ10 5 cells suspended in 50 L M199 containing 1% FBS were seeded in the upper compartment. The apparatus was then incubated for 5 hours at 37°C in a humidified chamber with 5% CO 2 to allow cell migration. After the incubation period, the filter was removed, and the upper side of the filter with the nonmigrated cells was scraped with a rubber policeman. The filters were fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter). Migration was quantified by counting cells of three random high-power fields (ϫ100) in each well, and all experiments were performed in quadruplicate.
Animal Model
The physiological response to administration of rhVEGF 165 and rhSF/HGF was investigated in a previously described rabbit ischemic hindlimb model. 37 All protocols were approved by the St Elizabeth's Institutional Animal Care and Use Committee. Twenty-seven male New Zealand White rabbits (3.5 to 4.0 kg) (Pine Acre Rabbitry, Norton, Mass) were anesthetized with a mixture of amine (50 mg/kg) and acepromazine (0.8 mg/kg) after premedication with xylazine (2 mg/kg). They underwent surgical removal of one femoral artery by a previously described technique. 37 In this model, the excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb is dependent on collateral vessels originating from the internal iliac artery.
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Design of the In Vivo Experiment
The dose of rhVEGF 165 used in the present experiment (500 g) has previously been shown to induce an optimal angiogenic effect of rhVEGF 165 with a single bolus administration protocol. 3, 38 To ensure a maximum effect of rhVEGF165 alone, we administered three separate injections of 500 g: the first dose locally (intra-arterially into the ischemic limb) and then two additional doses intravenously; the latter has also been shown to achieve a reliable biological effect. 39 Because the dose-response curves observed with rhVEGF 165 and rhSF/HGF on migration and proliferation of cultured ECs were similar (see "Results"), the same dose of SF/HGF (500 g per injection) was chosen for comparison.
Ten days after surgery (day 0) and after measurement of baseline body weight as well as baseline noninvasive and invasive hemodynamic parameters (see below), animals received a single intra-arterial bolus of rhSF/HGF (500 g, nϭ9), rhVEGF 165 (500 g, nϭ9), or vehicle solution (3 mL saline with 0.1% rabbit serum albumin [Sigma], nϭ9) administered as a bolus over 1 minute through a 3F end-hole infusion catheter (Tracker-18, Target Therapeutics) positioned in the internal iliac artery of the ischemic limb. On days 2 and 4, the same dose of drug (or placebo) was administered intravenously.
On day 30, all the measurements were repeated, and the animals were killed. The liver, kidney, and hindlimb muscles were weighed, and specimens of each were obtained for histological analysis. Muscle and kidney samples were also retrieved for microsphere analysis of tissue flow.
Lower Limb Calf Blood Pressure Index
Calf blood pressure was measured at days 0 and 30 in both hindlimbs with a Doppler flowmeter (model 1050, Parks Medical Electronics) and a cuff connected to a pressure manometer. 37, 40 The calf blood pressure index was defined for each rabbit as the ratio of systolic pressure of the ischemic limb to systolic pressure of the normal limb (ϫ100).
Angiography and Doppler Guidewire Measurements
Angiography and intra-arterial Doppler guidewire measurement of flow velocity were performed on day 0 and day 30 by previously described techniques. 37, 40 In addition to measurements performed at rest, endothelium-dependent and endothelium-independent responses were evaluated with intra-arterial administration of acetylcholine chloride and nitroprusside (Sigma) over 2 minutes via a constant infusion pump (1 mL/min). Each drug was administered into the iliac artery of the ischemic limb at a dose of 1.5 g ⅐ min Ϫ1 ⅐ kg Ϫ1 .
Doppler-Derived Blood Flow in the Ischemic Hindlimb
The luminal diameter of the internal iliac artery was determined by angiography at the site of the Doppler sample volume, at rest and after drug infusion, with an automated edge-detection system (Quantum 2000I; QCS) as previously described. 37 Doppler-derived flow was calculated as Q D ϭ(d 2 /4)(0.5ϫAPV), where Q D is Doppler-derived time-averaged flow, d is vessel diameter, and APV is time average of the spectral peak velocity. 41 The mean velocity was estimated as 0.5ϫAPV by assuming a time-averaged parabolic velocity profile across the vessel. The Doppler-derived flow calculated in this fashion has previously been validated in vivo. 41 In the ischemic hindlimb, the internal iliac artery supplied blood flow for the entire hindlimb. 37 
Angiographic Analysis of Collateral Vessels
Morphometric analysis of collateral vessel development in the ischemic limb was performed by use of the 4-second angiograms recorded after injection of contrast media into the internal iliac artery. A grid overlay composed of 2.5-mm-diameter circles arranged in rows spaced 5 mm apart was placed over the angiogram at the level of the medial thigh. The number of contrast-opacified arteries crossing over circles and the total number of circles encompassing the medial thigh area were counted in single-blind fashion. An angiographic score was calculated as the ratio of crossing opacified arteries divided by the total number of circles in the ischemic thigh. This angiographic score reflects vascular density in the medial thigh.
40,42
Measurement of Muscle, Renal, and Hepatic Blood Flow
Blood flow to hindlimb muscles and kidneys was evaluated by use of colored polystyrene spheres 15 m in diameter. 40, 42 Quantification of microspheres is based on analysis of a linear relationship between spectrophotometrically determined absorbance of dye and number of microspheres. Thus, after the invasive measurements described above were completed, two different sets of 3ϫ10 6 Dye-Trak colored microspheres (Triton Technology) were injected through a 3F Teflon catheter into the left ventricle at days 0 and 30. At each time point, the first injection of the set was performed under baseline conditions and the second after a nitroprusside infusion (15 g ⅐ min Ϫ1 ⅐ kg Ϫ1 ) into the abdominal aorta. Each time, a reference blood sample was withdrawn with a syringe pump (Sage 351, Orion Research) to collect microspheres at a constant rate of 1.2 mL/min from a peripheral artery (central ear artery). When the animals were killed, a total of 14 tissue samples (2 g each) from seven different muscles (tensor fasciae latae, vastus lateralis, vastus medialis, adductor, semimembranosus, gastrocnemius, and tibialis anterior) in each hindlimb (ischemic and nonischemic) were retrieved. Samples from right and left kidneys and from the liver were also collected and used (1) to control for right-left homogeneity of blood microsphere content and (2) to evaluate the effect of administered angiogenic factors on blood flow to nonischemic tissues. After tissue and blood sample digestion with potassium hydroxide, microsphere extraction by filtering, and complete dye removal with dimethyl formamide, each sample was analyzed by a conventional spectrophotometer (model 8452A, Hewlett Packard). 40, 42 From the optical density (OD) measurements, the muscle perfusion expressed in mL ⅐ min Ϫ1 ⅐ 100 g Ϫ1 was calculated from the following equation: blood flow of muscle sample (mL ⅐ min Ϫ1 ⅐ g Ϫ1 )ϭ(OD of tissue sample/OD of reference blood sample)ϫ[withdrawal rate of reference blood sample (mL/min)/ weight of tissue sample (g)].
Blood flow of muscle sample (mL ⅐ min Ϫ1 ⅐ g Ϫ1 )ϭ(OD of tissue sample/OD of reference blood sample)ϫ[withdrawal rate of reference blood sample (mL/min)/weight of tissue sample (g)].
Muscle blood flow in each hindlimb was expressed as the mean of the 14 samples. For each animal, muscle blood flow in the ischemic hindlimb was also expressed as a percentage of muscle blood flow in the nonischemic hindlimb.
Capillary Density
The extent of vascularity was further examined by measurement of the number of capillaries in light microscopic sections retrieved from ischemic and nonischemic hindlimbs, as previously described. 40 Tissue specimens were obtained as transverse sections from the adductor muscles and the semimembranosus muscles at the time of euthanization (day 30). Frozen sections were stained for alkaline phosphatase with an indoxyl tetrazolium method to detect capillary ECs and then were counterstained with eosin. 43 A total of 20 different fields under an ϫ20 objective from the two muscles were randomly selected, and the number of capillaries were counted to determine the capillary density (mean number of capillaries per square millimeter). To ensure that analysis of capillary density was not overestimated because of muscle atrophy, capillary density was also evaluated as a function of the number of muscle fibers in the histological section.
Muscle Weight
For each hindlimb, muscles were divided into three groups: external thigh, internal thigh, and calf. At the time the animals were killed, the weight of each group (including the samples used for microsphere and histological analyses) was measured in each hindlimb. In each animal, an index of muscle atrophy was calculated for each group of muscles and for the entire hindlimb as follows: index of muscle atrophyϭ[1Ϫ(muscle weight in ischemic hindlimb/muscle weight in nonischemic hindlimb)]ϫ100.
Histological Examination of Liver and Kidneys
To evaluate potential systemic effects of administered angiogenic factors, tissue samples from liver and kidney were systematically harvested, weighed, and cut into 5-mm slices to allow inspection for morphological abnormalities.
Statistical Analysis
Results were expressed as meanϮSEM. Statistical significance was evaluated by unpaired Student's t test for comparisons between two means, ANOVA followed by Scheffé's procedure for more than two means, and two-way ANOVA to test for interaction. A value of PϽ.05 was interpreted to denote statistical significance.
Results
SF/HGF Induces VEGF mRNA and Protein Expression in Cultured HVSMCs
Administration of 25 ng/mL rhSF/HGF to cultured HVSMCs resulted in time-dependent induction of VEGF mRNA expression, as demonstrated by Northern blot analysis (Fig 1A) . Whereas the level of VEGF mRNA was low to nondetectable among quiescent SMCs maintained in low-serum medium, induction of VEGF mRNA was already pronounced 3 hours after stimulation, peaked at 6 hours, and persisted for at least 24 hours. Induction of VEGF mRNA expression was dose dependent, with a maximal effect between 25 and 50 ng/mL rhSF/HGF (Fig 1B) . To exclude nonspecific effects, BSA was added to SMCs and yielded no change in VEGF mRNA baseline expression (Fig 1C) . PMA was used as a positive control. RT-PCR analysis (Fig 2A) disclosed equivalent induction of all three major VEGF isoforms, and semiquantitative evaluation of the VEGF 165 PCR product confirmed that peak induction occurred 6 hours after stimulation with rhSF/ HGF (2.9Ϯ0.13-fold increase compared with unstimulated controls). After 18 and 24 hours, VEGF 165 mRNA decreased to 2.4Ϯ0.16 and 2.3Ϯ0.11-fold, respectively (Fig 2B) .
Western blotting confirmed the effect of rhSF/HGF on VEGF expression at the protein level (Fig 3) .
In Vitro Effects of rhSF/HGF and rhVEGF 165 , Alone and Together, on EC Migration and Proliferation
The impact of rhSF/HGF and rhVEGF 165 on proliferation and migration of cultured HUVECs is shown in Fig 4. No statistical difference was detected in the response of ECs to the two cytokines over a concentration range of 0.1 to 1000 ng/mL. For rhSF/HGF, maximal effect (expressed as percent of baseline) on HUVEC proliferation was 139.1Ϯ13.4% and for rhVEGF 165 , 158.2Ϯ7.6%, PϭNS (Fig 4A) . Similarly, the maximal effect of rhSF/HGF and rhVEGF 165 on HUVEC Whereas quiescent SMCs contained very low or nondetectable levels of VEGF mRNA, an increase was visible 3 hours after stimulation, peaked at 6 hours, and persisted through 24 hours. B, Northern blot analysis of VEGF mRNA at 4 hours, with concentrations of rhSF/HGF as indicated. Induction of VEGF mRNA was dose-dependent, achieving a maximal effect between 25 and 100 ng/mL rhSF/HGF. C, To exclude nonspecific effects, 50 ng/mL BSA was added to HVSMCs and showed no change in VEGF mRNA expression. PMA was used as positive control. migration was 233.9Ϯ6.4% and 278.1Ϯ6.7%, respectively, PϭNS (Fig 4B) .
The combined effect of rhSF/HGF and rhVEGF 165 administered together was at least additive for both EC proliferation (PϽ.01, Fig 4A) and migration (PϽ.0001, Fig 4B) . In addition, when submaximal concentrations (1, 10, 50, and 100 ng/mL) were used, a synergistic effect of the two cytokines was observed on EC migration (PϽ.0001). At 10 ng/mL, for example, rhSF/HGFϩrhVEGF 165 250.3% of baseline versus an expected additive value of ϩ178.9% (rhSF/HGF alone76.3% and rhVEGF 165 alone102.6%; PϽ.0001).
Representative examples of the EC migration assay performed at a growth factor concentration of 10 ng/mL are shown in Fig 5 . Similar results were obtained with human microvascular ECs (data not shown).
Effect of rhSF/HGF and rhVEGF 165 on Collateral Vessel Development in Ischemic Hindlimb
On the basis of the above results showing similar direct effects of both cytokines on ECs in vitro, we choose the same doses of rhSF/HGF and rhVEGF 165 to evaluate their respective effects on angiogenesis in vivo, using the ischemic hindlimb model. We speculated that in addition to the direct effect of SF/HGF on EC proliferation and the synergistic effect, when administered with VEGF, on EC migration, the potential for SF/HGF to induce VEGF synthesis in SMCs could yield a superior effect, relative to rhVEGF 165 alone, on angiogenesis in vivo.
The quantitative analysis of collateral blood vessel development in the medial thigh of rabbits with hindlimb ischemia is summarized in Fig 6A. Before treatment (day 0), angiographic scores did not differ significantly among the experimental groups. By day 30, the angiographic score in both rhVEGF 165 -and rhSF/HGF-treated groups exceeded (PϽ.001) that of the control group (controlϭ0.55Ϯ0.03; rhVEGF 165 ϭ0.71Ϯ0.04; rhSF/HGFϭ0.89Ϯ0.04). Moreover, the angiographic score for the rhSF/HGF group was significantly higher than that of the rhVEGF 165 group (Pϭ.02). 
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The impact of rhSF/HGF and rhVEGF 165 on vascular density was also investigated at the capillary level, with light microscopy used to quantify capillaries/mm 2 in tissue sections harvested at necropsy from the medial thigh muscles of the ischemic and nonischemic limbs. Morphometric analysis revealed that capillary density was significantly higher (PϽ.001) in the rhVEGF 165 -and rhSF/HGFtreated groups than in the control group (controlϭ153Ϯ10/mm 2 ; rhVEGF 165 ϭ231Ϯ14/mm 2 ; and rhSF/HGFϭ288Ϯ18/mm 2 ). Capillary density in the rhSF/HGF group was also significantly higher than in the rhVEGF 165 group (Pϭ.02) (Fig 6B) . Analysis of the ratio of capillaries to muscle fiber yielded similar results (controlϭ0.41Ϯ0.03; rhVEGF 165 ϭ0.65Ϯ0.04; and rhSF/HGFϭ0.84Ϯ0.05).
Analysis of capillary density and ratio of capillaries to muscle fiber in sections from medial thigh muscles of the nonischemic limb showed no differences among groups (controlϭ201Ϯ8; rhVEGF 165 ϭ204Ϯ8; and rhSF/HGFϭ210Ϯ9; PϭNS) (Fig 6B) .
Representative examples of histological sections stained for alkaline phosphatase to identify capillary density in the three experimental groups are shown in Fig 8. 
Effect of rhSF/HGF and rhVEGF 165 on Pressure Perfusion Ratio
Calf blood pressure ratio was similar in all groups at day 0. By day 30, the blood pressure ratio had improved in all groups; in the rhVEGF 165 -and rhSF/HGF-treated groups, however, the blood pressure ratio was higher (PϽ.01) than in the control group (controlϭ0.51Ϯ0.05; rhVEGF 165 ϭ0.71Ϯ0.04; and rhSF/HGFϭ0.88Ϯ0.04). The blood pressure ratio observed in the rabbits treated with rhSF/HGF was significantly higher than that observed in rabbits treated with rhVEGF 165 (PϽ.05).
Effect of rhSF/HGF and rhVEGF 165 on Iliac Arterial Blood Flow
Blood flow parameters were measured from the Dopplertipped guidewire positioned in the internal iliac artery of the ischemic limb at days 0 and 30 (Fig 9A) . At day 0, there were no differences among groups in resting or maximum flow. At day 30, flow at rest was higher in rhVEGF-(PϽ.05) and rhSF/HGF-treated animals (PՅ.005) than in controls (controlϭ17.9Ϯ0.9 mL/min; rhVEGF 165 ϭ21.2Ϯ0.7 mL/min; and rhSF/HGFϭ23.9Ϯ1.2 mL/min). Maximum flow after nitroprusside infusion was significantly higher (PϽ.004) in both rhVEGF 165 -and rhSF/HGF-treated groups, compared with the maximum flow in the control group (controlϭ36.1Ϯ2.3 mL/min; rhVEGF 165 ϭ48.0Ϯ2.7 mL/min; and rhSF/ HGFϭ59.4Ϯ3.7 mL/min). Maximum flow in the rhSF/ HGF-treated animals was higher than in the rhVEGF 165 -treated animals (Pϭ.02). The significant increase in maximum flow in the rhVEGF 165 -and rhSF/HGF-treated rabbits resulted in a significantly higher (PϽ.005) flow reserve than in the control group (controlϭ2.01Ϯ0.06; rhVEGF 165 ϭ2.26Ϯ0.06; and rhSF/HGFϭ2.47Ϯ0.05). The flow reserve in the rhSF/ HGF-treated animals was also significantly higher than that of the rhVEGF 165 -treated animals (Pϭ.016). At day 30, number of vessels is significantly greater in rhVEGF-and rhSF/HGF-treated groups. Response to rhSF/HGF is significantly more pronounced than response to rhVEGF (Pϭ.02). *PϽ.001 vs control; #PϽ.05 vs VEGF. B, Capillary density evaluated at day 30 in histological sections of medial thigh muscles of nonischemic and ischemic limbs. In nonischemic limb, capillary density is not different among groups. In ischemic limb, rhVEGF and rhSF/HGF significantly increase capillary density. Effect of rhSF/HGF is significantly more pronounced than effect of VEGF (Pϭ.018). *PϽ.001 vs control; #PϽ.05 vs VEGF. rhVEGF 165 -treated animals (500 gϫ3, B) .
Effect of rhSF/HGF and rhVEGF 165 on Muscle Blood Flow
Muscle blood flow, assessed with colored microspheres, was determined for days 0 and 30 ( Fig 9B) . In each animal, the muscle blood flow in the ischemic limb was expressed as a percentage of the muscle flow measured in the nonischemic limb (see above). The homogeneity of microsphere distribution was verified by measurement of blood flow to the right and left kidneys (rϭ.99; slopeϭ0.97Ϯ0.04, interceptϭ0.14Ϯ0.10).
At day 0, there were no differences among groups for muscle flow index measured at rest (controlϭ65.6Ϯ3.9%; rhVEGF 165 ϭ62.9Ϯ4.2%; and rhSF/HGFϭ64.6Ϯ3.7%; PϭNS) or after administration of nitroprusside (controlϭ45.4Ϯ3.0%; rhVEGF 165 ϭ44.4Ϯ3.7%; and rhSF/HGFϭ39.8Ϯ2.9%; PϭNS). At day 30, muscle flow index at rest was higher in rhVEGF 165 and rhSF/HGF-treated animals (PϽ.002) than in controls (controlϭ71.1Ϯ2.3%; rhVEGF 165 ϭ87.6Ϯ3.7%; and rhSF/ HGFϭ99.1Ϯ3.4%). The muscle flow index measured after nitroprusside was significantly higher (PϽ.0005) in both rhVEGF 165 -and rhSF/HGF-treated groups than in the control group (controlϭ49.1Ϯ3.9%; rhVEGF 165 ϭ66.9Ϯ3.7%; and rhSF/ HGFϭ80.3Ϯ3.3%). The muscle flow index after nitroprusside was also higher for the rhSF/HGF-treated than in the rhVEGF 165 -treated animals (Pϭ.01).
Effect of rhSF/HGF and rhVEGF 165 on Muscle Atrophy
Muscle atrophy, evaluated by the muscle atrophy index (as described above), was significantly reduced in animals that received rhVEGF 165 or rhSF/HGF (PϽ.01) compared with controls (controlϭ28.67Ϯ2.47%; rhVEGF 165 ϭ14.25Ϯ2.52%; and rhSF/HGFϭ4.27Ϯ2.65%). The effect observed in the rhSF/HGF group was significantly greater than that observed in the rhVEGF 165 group (Pϭ.013) ( Table 1 ).
Systemic Effects of rhSF/HGF and rhVEGF 165 )
Although a trend toward greater weight gain was observed in rhVEGF 165 -and rhSF/HGF-treated animals, there were no significant differences among groups. Similarly, neither the weight nor the regional blood flow in liver or kidney differed among the groups. Blinded examination of microscopic sections from remote organ sites disclosed no pathological findings ( Table 2) .
Discussion
SF/HGF is a pleiotropic growth factor; its receptor, c-Met, is widely expressed on different cell populations, including both ECs and vascular SMCs. 24 Cells transfected with full-length met cDNA respond to SF/HGF with a wide spectrum of biological effects. 44 We therefore considered the possibility that SF/HGF could also upregulate VEGF expression in SMCs. In our first series of in vitro experiments, we could in fact demonstrate that SF/HGF upregulates VEGF expression in HVSMCs. Induction of VEGF mRNA by SF/HGF has previously been suggested by results obtained with implanted Matrigel. 45 In that previous report, neither the identity of the cells responsible for the increase in VEGF mRNA nor the possibility of an increase in VEGF at the protein level was investigated. The present results establish that SMCs increase both VEGF mRNA and protein production after stimulation by SF/HGF. Furthermore, expression of all three principal VEGF isoforms was augmented.
The second series of in vitro experiments indicates that the effect of SF/HGF on EC migration and proliferation is similar to that induced by VEGF. When SF/HGF and VEGF are administered together, however, the mitogenic and chemotactic response of cultured ECs exceeds that achieved with either cytokine alone. Taken together, these findings suggest that in a milieu in which both ECs and SMCs are present, as is the case in vivo, SF/HGF may exert a potent combination of direct and indirect effects, including direct effects on ECs and indirect effects mediated via an increase in the production of VEGF. The consequence of such combined effects would be expected to be a potent means for stimulating angiogenesis in vivo.
The results of the in vivo experiments, in fact, confirm this notion. Experiments performed in the rabbit ischemic hind- 
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limb model established that SF/HGF may be used therapeutically to augment collateral vessel development and blood flow to ischemic tissue. Previous investigators have evaluated the effect of SF/HGF in alternative in vivo assays, including Matrigel plug and cornea pocket assays. 16, 18 The present observations extend these previous results by showing that the neovasculature that develops in response to SF/HGF is functional, as indicated by the concomitant increase in arterial blood flow in the ischemic hindlimb, improvement in skeletal muscle perfusion, and a significant reduction in muscle atrophy.
The demonstration of a potent therapeutic effect of exogenously administered SF/HGF on angiogenesis in this ischemic hindlimb model is consistent with previous descriptions of transient expression in skeletal muscle during embryogenesis and after ischemic injury, 14 in contrast to absent expression in normal adult muscle. 13, 14 The possibility that SF/HGF may play a key role in modulating angiogenesis that develops in response to ischemia is further supported by the recent finding that expression of SF/HGF is enhanced after myocardial ischemia and reperfusion. 20 The present in vivo studies also indicate that SF/HGFinduced neovascularity exceeds that achieved with VEGF. Despite a similar dose-response relationship in vitro and the same schedule of administration (500 gϫ3) in vivo, angiographic as well as histological evidence of angiogenesis in animals receiving SF/HGF was more marked than that in those treated with VEGF. These in vivo results extend our in vitro findings by suggesting that the ability of SF/HGF to induce angiogenesis by direct effects on EC proliferation and migration may be potentiated in vivo by the ability to induce angiogenesis indirectly by upregulating one or more cytokines, as shown here for VEGF.
Direct comparison of SF/HGF and VEGF carried out in these in vivo studies suggests that EC specificity is not necessarily an advantageous feature for cytokines designed to promote angiogenesis. In fact, from the standpoint of bioactivity, the in vivo results suggest that the pleiotropic effects of nonspecific EC mitogens such as SF/HGF may constitute an important means of optimizing neovascularization of ischemic tissues. The potential liability of pleiotropic effects associated with a non-EC-specific mitogen is the risk of stimulating superfluous cell populations. In this regard, it is noteworthy that no pathological consequences were observed with the dose and protocol of administration of SF/HGF used for these experiments. In particular, body weight was not altered and no evidence of angiogenesis or increased blood flow was observed in nonischemic tissues. In addition, whereas previous reports have suggested that SF/HGF administration is associated with a growth-promoting effect on liver and kidney, 15,46 -48 no such There were no significant differences among groups for any parameter. *%ϭ(final body weightϪbaseline body weight)/baseline body weight (ϫ100). †%ϭorgan weight/final body weight (ϫ100).
effect was observed in our study. It is important to point out, however, that in these previous reports, growth-promoting effects of SF/HGF were demonstrated in the case of injured organs 15, 46, 47 and/or continuous administration of the angiogenic cytokine. 47, 48 The absence of accompanying pathological effects in the present series of experiments as well as in other reported work 46 is consistent with the suggestion that the in vivo response to SF/HGF is facilitated by a priming stimulus. Indeed, similar site specificity has been demonstrated for basic fibroblast growth factor. 7 The above-cited work of Ono et al 20 suggested that local upregulation of the c-Met receptor acts to regulate the extent of SF/HGF bioactivity. A similar paradigm has been described for VEGF, in which site specificity appears to be due in part to paracrine upregulation of the KDR receptor by factors derived from hypoxic myocytes. 49 It is also worth noting that previous studies have established that stimulation of the c-Met receptor in vascular SMCs does not evoke a proliferative response. 24, 49 Moreover, the risk of potentially unwanted effects in noninjured organs may be avoided by a protocol of restricted administration. In this regard, it is fortuitous that the time interval required for neovascularization of ischemic tissues in animals 3, 39, 50 and patients 9,10 is typically Ͻ30 days.
